Free Trial
NASDAQ:ENTA

Enanta Pharmaceuticals Q1 2025 Earnings Report

Enanta Pharmaceuticals logo
$5.97 -0.19 (-3.08%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$5.93 -0.04 (-0.74%)
As of 05/30/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals EPS Results

Actual EPS
-$1.05
Consensus EPS
-$1.16
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Enanta Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$17.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enanta Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, February 10, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Enanta Pharmaceuticals' Q3 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Enanta Pharmaceuticals Earnings Headlines

Do You Believe In President Trump? Answer This 1 Question
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More Enanta Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA), a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

View Enanta Pharmaceuticals Profile

More Earnings Resources from MarketBeat